fbpx JLABS Company News | JLABS

News


In the media

J&J launches digital skincare challenge

By Dominic Tyer

Read full story
In the media

Experts weigh in: How will health technology advance in 2018?

By -

Read full story
In the media

PreCAAP Company: Tracery Opthalmics Wins $50K First Prize at JLABS AI for Drug Discovery QuickFire Challenge

By -

Read full story

Mobile Wellness Challenge

HealthTech_QFC_Video_180309
Mobile Wellness Challenge
Challenge ended

$25,000 + Optional residency at JLABS

Digital Health

FibriCheck Mobile Wellness QFC Winner

FibriCheck is a medically certified screening and monitoring application on prescription for the detection of irregular heart rhythms, including atrial fibrillation. FibriCheck is a software-only solution that only requires the user to place his/her finger on the camera of the smartphone to measure the cardiac rhythm anywhere and anytime. All the information is automatically shared with a medical professional in order to get a faster diagnosis, resulting in an adequate treatment plan.

 

The Challenge

Image paragraph

Mobile technology is empowering patients and providers, giving them greater control over their health and access to information, as noted in a recent report by the Deloitte Centre for Health Solutions. According to MobiHealthNews, 36 health apps and connected solutions were approved by the FDA in 2016 alone.

The Mobile Wellness Management Challenge - the first in the Health Technology Innovator QuickFire Challenge series - will kick off March 9, 2018 and run through June 1, 2018. Ongoing advances in health technology provide multiple touch points to positively impact patients. Health Technology can be a primary mode of interface, a service offering, or a layer on top of traditional device and/or therapeutic offerings. Wellness and behavioral management applications integrated into mobile and wireless technology are propelling improvements in health outcomes, healthcare services and health research.

Developments in health technology, specifically within mobile, offer the ability to drastically scale improved health care across the globe. Providing better access and care in more places in the world is one of Johnson & Johnson's key commitments in reaching a healthier 2020.

Johnson & Johnson Innovation, JLABS is looking to reward one year of residency at a JLABS location , including mentorship to the individuals or teams who submit the best ideas, technologies, or solutions that are focused around using mobile health technology to advance healthcare. At Johnson & Johnson Innovation, JLABS our goal is to improve the health and wellness of people around the world, and we invite you to join us on this mission!

Rewards and benefits

Funding up to $25,000
  • Residency at an available JLABS location
  • Acceptance into the Health Tech @ JLABS program
  • Mentoring & coaching from Johnson & Johnson Innovation experts

QuickFire Challenge innovation focus areas:

We are looking for entrepreneurs & innovators with the best ideas, technologies, or solutions across all stages (ideation, pre-clinical, clinical, post-approval) that are using mobile health technology to advance any of these areas:

  1. Interception and Prevention of Disease
  2. Intelligent devices for therapy delivery
  3. Customer collaboration with providers and payers
  4. Ubiquitous and accessible healthcare

Timeline

EST
Applications Open (SXSW launch)
Africa/Abidjan
Submission Deadline
EST
Judging Commences
Africa/Abidjan
Winners announced

Application process

A panel of reviewers and judges will evaluate submissions based on their ability to meet the following criteria:

  • Scientific/Technical Excellence
  • Novelty
  • Feasibility/Practicality
  • Perceived commercialization potential
  • Clarity on milestones and deliverables
  • Quality of Team and Resources
  • Plan for use of funds
  • Integration of mobile technology


Deadline to apply is June 8, 2018
Winner(s) will be announced in Fall 2018

Apply Now

Submit your idea today!


Don’t miss the deadline

IBD Stress Test

IBD Stress Test QuickFire Challenge
Challenge ended

Up to $50,000 in grants + Access to mentorship

Consumer Health
Digital Health

The University of Oxford

 

The Translational Gastroenterology Unit (TGU) at the University of Oxford aims to blend basic science with clinical studies to improve care, find the cause, and develop a cure for diseases of the GI tract. Their work aims to define better markers that predict how patients respond to treatments for inflammatory bowel disease. They leverage IBD genetics studies performed in the UK as well as the community of researchers studying genetic risks for ulcerative colitis to perform large association studies followed by functional analyses to assess how best to use virology data.

Overview

IBD Stress Test QuickFire Challenge

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, is characterized by chronic inflammation of the digestive tract. Symptoms can include severe abdominal pain, diarrhea, fatigue, and weight loss. IBD affects over 1.6 million people in the USA according to the Crohn’s and Colitis Foundation of America, and according to the National Reviews Gastroenterol & Hepatology, there are currently 2.5 million sufferers in Europe and rising incidences in newly industrialized countries in Africa, Asia, and South America. Diagnosis is challenging and often delayed, leading many patients to progress to advanced stages of the disease, requiring surgery. Increasing evidence indicates that genetic and microbial factors, combined with environmental and lifestyle factors including infections, antibiotics, and diet, likely impact the development of IBD.

What if we could better diagnose, treat, and prevent IBD by using modern technology to evaluate an individual’s state of immune and gastrointestinal health?

There is a growing hypothesis that health and disease are characterized by a person’s ability to adapt to a diverse collection of stimuli or “stressors”. Therefore, it might be possible to predict one’s risk of disease by evaluating responses to stressors. Assessing an individual’s response to stressors could reveal early signs of disease that would not be identifiable while an individual is at rest. Examples include the cardiac stress test, which measures the heart’s response to external stress induced by exercise to diagnose heart disease, and the glucose tolerance test, which measures the body’s ability to process sugar after ingesting a glucose solution to diagnose gestational diabetes. Eventually we may be able to optimize health by routinely measuring responses to stressors and stimuli that people experience on an everyday basis!

The goal of this QuickFire Challenge is to evaluate immune and gastrointestinal health and ultimately predict risk of IBD by assessing the response of the immune and gastrointestinal systems to challenges with stressors. If you have an idea for a product, technology, or methodology to investigate the response of the human immune and gastrointestinal systems to stressors, Janssen Research & Development is awarding up to $50,000 with possible mentorship opportunities to help make that idea a reality.

Criteria

Please note: These are preferred and not required criteria.

Proposals containing the following criteria are preferred, but are not required. Please keep in mind that no idea is too big or too early for consideration. Applications that clearly describe a concept or path forward to achieve these goals will also be considered during evaluation. 

Products, technologies, and methodologies evaluated in-human or using human samples (e.g., ex vivo) are preferred. However, in vivo, in vitro, or other types of model systems are also encouraged. Proposals that demonstrate proof-of-concept are preferred. For example, proposals demonstrating that the response to stressors correlates with specific phenotypes, can differentiate between varying states of health, or can predict risk of disease.

Examples

Please note that the following are meant to represent examples only. If you have an idea that falls outside of these examples, we strongly encourage you to apply!

Stressors/Stimuli

Examples of stressors or stimuli that may be evaluated include but are not limited to:

  • Dietary Factors: There is increasing evidence that diet might contribute to the development of IBD. Proposals for evaluating the ability of the human immune and gastrointestinal systems to adapt upon challenge with dietary stimuli are sought.
  • Infection or Microbial Factors: Evidence suggests that viral or bacterial infections and exposure to microbial stimuli might represent triggers for IBD. Proposals for evaluating the ability of the human immune and gastrointestinal systems to adapt upon challenge with infection or microbial stimuli are sought.
  • Other Environmental or Lifestyle Factors: Proposals for evaluating the response of the human immune and gastrointestinal systems to other types of stressors, for example, specific environmental or lifestyle stimuli associated with IBD, are also strongly encouraged.

Responses to Stressors/Stimuli

Examples of responses to stressors or stimuli that may be evaluated include but are not limited to:

  • Measures of intestinal permeability and gut barrier health
  • Innate immune system function, including trained immunity
  • Measures of immune tolerance, including oral tolerance
  • Cellular stress responses
  • T-cell exhaustion

Proposals for evaluating other types of responses relevant to IBD are highly encouraged.

Why this challenge matters

 

A significant need exists to accurately predict who is at high risk of developing IBD so that safe interventions can be provided to prevent progression to clinical disease. Janssen Research & Development and Johnson & Johnson Innovation have a successful history in creating new markets, delivering breakthrough innovation and establishing strong partnerships built on a shared vision. We believe a good idea can come from anywhere, and it’s our goal to break through the noise of the crowded landscape and to accelerate the development of novel technologies, treatments, and pharmaceuticals to provide solutions to patients.

Application Process

 

Proposals should include: (1) definition of the stressor(s) to be applied; (2) definition of the human population or model system used to evaluate the response to the stressor; and (3) definition of how the response will be measured.

The goal of this QuickFire Challenge is to employ response to stressors in order to evaluate immune and gastrointestinal health and to ultimately predict risk of IBD. Solutions will be evaluated by a panel of reviewers and judges on their ability to meet the following criteria:
• Potential to impact healthcare outcomes in a strategic area of interest
• Uniqueness of solution & level of competition in current market
• Quality & feasibility of technology
• Team credibility & capabilities
• Clarity of plan: Milestones & defined go/no go decisions

America/New_York
Applications Open
America/New_York
Applications Deadline
America/New_York
Judging Commences
November 2018
Winners Announced

Reward

Up to $50,000
  • Up to $50,000 in grants
  • Access to a network of Johnson & Johnson Innovation experts

Submit your idea today!


Don’t miss the deadline

 

About Janssen Pharmaceutical, Companies of Johnson & Johnson

At the Janssen Pharmaceutical, Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science.

We are Janssen. We collaborate with the world for the health of everyone in it. Learn more at www.janssen.com. Follow us at @JanssenGlobal.

 

 


About Johnson & Johnson Innovation, JLABS

Johnson & Johnson Innovation LLC focuses on accelerating all stages of innovation worldwide and forming collaborations between entrepreneurs and Johnson & Johnson’s global healthcare businesses. Johnson & Johnson Innovation provides scientists, entrepreneurs and emerging companies with one stop access to science and technology experts who can facilitate collaborations across the pharmaceutical, medical device and consumer companies of Johnson & Johnson. Under the Johnson & Johnson Innovation umbrella of businesses, we connect with innovators through our regional Innovation Centers, Johnson & Johnson Innovation, JLABS (JLABS), Johnson & Johnson Innovation – JJDC, Inc. and our Business Development teams to create customized deals and novel collaborations that speed development of innovations to solve unmet needs in patients. For more information, visit www.jnjinnovation.com or follow @JNJInnovation.

Johnson & Johnson Innovation, JLABS (JLABS) is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS achieves this by providing the optimal environment for emerging companies to catalyze growth and optimize their research and development by opening them to vital industry connections, delivering entrepreneurial programs and providing a capital-efficient, flexible platform where they can transform the scientific discoveries of today into the breakthrough healthcare solutions of tomorrow.  At JLABS we value great ideas and are passionate about removing obstacles to success to help innovators unleash the potential of their early scientific discoveries.  JLABS is a no-strings-attached model, which means entrepreneurs are free to develop their science while holding on to their intellectual property.  JLABS is open to entrepreneurs across a broad healthcare spectrum including pharmaceutical, medical device, consumer and digital health sectors.

JLABS currently has locations in innovation hot spots across the world and produces entrepreneurial programs and campaigns to seek out the best science, like the QuickFire Challenges around the globe. The JLABS flagship opened in 2012 in San Diego at Janssen's West Coast Research Center, and since then, has established two locations in San Francisco - one through a collaboration with the California Institute for Quantitative Biosciences (QB3) and a second standalone facility in South San Francisco.  JLABS is also located in Boston through a collaboration with LabCentral, in Lowell, Massachusetts through a collaboration with UMass, in Houston through a collaboration with the Texas Medical Center (TMC), in Toronto through a collaboration with the Ontario Government and the University of Toronto. New JLABS in NYC and Shanghai have been announced, and in February 2018, the Belgium-based JLINX incubator began transitioning into a JLABS, making this the first JLABS in Europe.  For more information about JLABS, please visit www.jlabs.jnjinnovation.com.

Other news

Want to know more about the JLABS Portfolio?

By JLABS

Read full story

Lung Cancer Innovation QuickFire Challenge

Jlab_Quickfire-2018-06-12
lung cancer
Challenge ended

$750,000 (¥4.7M) in Grants + Residency + Mentoring

Surgical Oncology
Therapeutics

                        点击这里阅读中文

Awardees

Lung%20Cancer%20Innovation%20QFC%20Awardees.png

 

DNX Biopharmaceuticals

 

DNX Bio is a biopharmaceutical company developing long-acting therapeutic proteins for the treatment of patients with life-long diseases. Founded in 2014 and headquartered in Irvine, CA, USA, DNX is pursuing the development of new therapeutic proteins utilizing a 21st century, half-life extension platform technology known as PASylation, which is in-licensed from XL-protein GmbH. XLp has granted DNX a worldwide exclusive license under its patents and know-how related to the PASylation technology to develop and commercialize several PASylated products.

 

Hawkeye Bio

 

Hawkeye Bio was launched in 2018 in California to commercialize novel, clinically validated breath analytics for the detection of lung cancer. Lung cancer is the leading cause of cancer deaths among both men and women[1]. Lung cancer often has no symptoms until it has metastasized, because there are few specialized nerves (pain receptors) in the lungs. Lung cancer is diagnosed late 84% of the time, when treatment options are more limited. Despite progress in biomarker discovery and targeted therapy, lung cancer mortality remains unacceptably high worldwide. Hawkeye’s mission is lung cancer interception to bring about a solution to this problem.

 

NE Scientific

 

NE Scientific is a Boston-based startup company developing a surgical guidance software for supporting physicians in targeting tissues during the percutaneous ablation of liver and lung tumors. The Accublate (TM) guidance software simulates in real-time the physics taking place during the ablation and determines the ablation volume in a patient-specific way. This information is generated intraoperatively and overlaid to CT images of the patient, helping the physician in achieving a complete treatment of all malignant tissues.

[1]HawkeyeBio.com, 2019

The Challenge

Image Paragraph

The average person breathes in 432 liters of oxygen every single day, a vital component in sustaining the trillions of cells in the body. Humans can survive just a few minutes without oxygen.  To that end, it is essential that we protect our lungs.  

Is there a way to cleanse the lungs after exposure to carcinogens much like a toothbrush cleanses the mouth after eating? Is there a way to shield the lungs from carcinogens much like sunscreen shields us from damaging UV exposure?  These are a few of the provocative ideas Johnson & Johnson Innovation hopes to trigger through the Lung Cancer Innovation QuickFire Challenge. 

Lung cancer is a major cause of global morbidity and mortality with approximately 1.6 million deaths globally each year.  Unlike other diseases, lung cancer is caused by prolonged environmental exposure to carcinogens that overwhelm a human’s natural defenses and result in inflammation, genomic changes and ultimately tumor growth.  Although a global epidemic, it is unclear what makes one individual over another more susceptible to developing lung cancer.  

Johnson & Johnson (China) Investment Ltd. and Johnson & Johnson Innovation LLC are committed to prioritizing lung health.  How do we leverage the totality of science and technology to achieve comprehensive lung health -  to ultimately prevent, intercept and cure lung cancer?

Up to three innovators with the best ideas, technologies, or solutions that improves human healthcare related to preventing, intercepting or curing lung cancer will be awarded up to a total of $750,000 in grants, a voucher for one year of residency at JLABS @ Shanghai (optional), including a laboratory bench, workstation and access to the JLABS community, and mentorship from Johnson & Johnson Innovation and/or its affiliates.

Reward

Up to $750,000 (¥4,775,850) in total grants 
  • 1 year residency at JLABS @ Shanghai (Optional)
  • Mentoring & coaching from experts from Johnson & Johnson Innovation and/or its affiliates

Areas of Interest

We encourage applications from innovators working on all aspects of lung health, including solutions focused on Lung Cancer:

  • Prevention: Approaches to identify risks and for warding off onset of lung cancer
  • Interception: Arrest lung cancer as it develops, prior to clinical onset
  • Cures: Completely eliminate presence of lung cancer and reverse damage to restore full health

Please keep in mind that no idea is too big or too early for consideration. Applications that clearly describe a concept or path forward to achieve these goals will also be considered during evaluation.  

We are interested in applications addressing the full spectrum of lung health. Specific areas of interest include, but are not limited to: 

  • To develop approaches to reduce, prevent, or protect from exposure to respiratory carcinogen, including novel approaches to smoking cessation 
  • To develop approaches to measure the exposure to and biological effect from respiratory carcinogens
  • To develop diagnostics/biomarkers to detect pre-cancers or early-stage malignant lesions
  • To develop approaches, including surgical, medical, behavioral, digital or others, to prevent or intercept lung carcinogenesis
  • To discover new tools for diagnosis and extirpation of curable lung cancers
  • To develop new treatments or treatment modalities for the cure of lung cancer

Approaches should include the following areas:

  • Pharmaceuticals
  • Consumer products
  • Medical devices
  • Global public health
  • Health technologies
  • Cross-sector initiatives – an integration of one or more the aforementioned areas of focus 

Application Process

Solutions will be evaluated by a panel of reviewers and judges on their ability to meet the following criteria:

  • Potential impact
  • Uniqueness of solution & level of competition in current market
  • Quality & feasibility of technology
  • Team credibility & capabilities
  • Idea submission outlines interest in the innovation ecosystem in Shanghai (optional)

Timeline

June 14, 2018 (China Time)
Applications Open
September 21, 2018 (China Time)
Submission Deadline
Spring 2019
Winner Announcement at JLABS @ Shanghai Launch

Apply Now


Don’t miss the deadline

Why this challenge matters to us

We believe a good idea can come from anywhere, and it’s our goal to find new and innovative technologies that provide solutions to patients from across the world. Working together, we can spark the next great idea that will change the trajectory of health.

FAQs

 

Q: What if I’m having trouble accessing the portal/website?

A: Make sure your browser is up to date and accepting cookies. You can contact customer service at [email protected] if you are having technical difficulties as well.

 

Q: Is residency at JLABS @ Shanghai required?

A: No. Residency is encouraged but optional.

 

Q: Do I need to reside in Shanghai or a Chinese entity in order to apply?

A: No. We are seeking innovations globally.

 

Q: For prizes involving residency at JLABS, what does that entail and for how many people?

A: For challenges involving residency at JLABS, that entails 1 lab bench and 1 workstation (desk) for 2 people maximum. If you have more employees, additional footprint can be rented.

 

Q: For prizes involving residency at JLABS, are there any expenses not covered by JLABS?

A: Each applicant will be required to submit to a background check, which is subject to a minimal fee.  We also collect a deposit that is refundable at the end of the lease term. There may be other expenses, but this will be dependent on the work that the company is doing in JLABS.  There may also be fees associated with EH&S waste, specialty equipment, printing and phone calls.

 

Q: Will JLABS pay for my living costs, relocation or visas?

A: No, any additional fees and paperwork are up to the winner.

 

Q: Can I submit supporting documents (for example a video) as part of my application? 

A: You will have the opportunity and are encouraged to upload supporting materials such as slide decks, research papers, and videos as part of your application. You may submit a video along with your typed responses. Maximum length is 2 minutes.

 

Q: Is it ok if some of the information I submit is confidential?

A: Do not submit confidential information. Only non-confidential information should be submitted and anything you submit will be treated as non-confidential.

 

Q: What happens with IP (Intellectual Property)?

A: As this is a no strings attached arrangement, JLABS does not acquire any IP.  Any IP creation and/or protection remains the sole responsibility of the inventors.

 

Q: Is a patent required to apply?

A: No, a patent is not required to apply.  However, you should not submit any information that you wish to keep confidential or that may negatively impact upon the future patentability of your invention.

 

Q: What kind of science / technology is appropriate for the Challenges? 

A: We encourage all to apply. Find out more about what areas we desire to explore here: https://www.jnjinnovation.com/partnering

 

Q: Who is eligible to apply?

A: Each Challenge has its own terms & conditions that can be found prior to filling out the application.

 

Q: What are the specific criteria for application?

A:  Solutions will be evaluated by a panel of reviewers and judges on their ability to meet the following criteria:

  • Potential impact
  • Uniqueness of solution & level of competition in current market
  • Quality & feasibility of technology
  • Team credibility & capabilities
  • Idea submission outlines interest in the innovation ecosystem in Shanghai (optional)

 

Q: Who can I contact if I have questions about the Challenges or the application process?

A: Please contact [email protected] with any questions.

 

Q: Where do I apply? And do I have to complete the application in one sitting?

A: Apply at https://jlabs.jnjinnovation.com/form/lung-qfc-apply. You are able to save your work and log back in to finish at a later time if needed.

About Johnson and Johnson Innovation, JLABS

Picture1.png

 

Johnson & Johnson Innovation, JLABS (JLABS) is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS achieves this by providing the optimal environment for emerging companies to catalyze growth and optimize their research and development by opening them to vital industry connections, delivering entrepreneurial programs and providing a capital-efficient, flexible platform where they can transform the scientific discoveries of today into the breakthrough healthcare solutions of tomorrow.  At JLABS we value great ideas and are passionate about removing obstacles to success to help innovators unleash the potential of their early scientific discoveries.  JLABS is a no-strings-attached model, which means entrepreneurs are free to develop their science while holding on to their intellectual property.  JLABS is open to entrepreneurs across a broad healthcare spectrum including pharmaceutical, medical device, consumer and digital health sectors.

JLABS currently has locations in innovation hot spots across the world and produces entrepreneurial programs and campaigns to seek out the best science, like the QuickFire Challenges around the globe. The JLABS flagship opened in 2012 in San Diego at Janssen's West Coast Research Center, and since then, has established two locations in San Francisco - one through a collaboration with the California Institute for Quantitative Biosciences (QB3) and a second standalone facility in South San Francisco.  JLABS is also located in Boston through a collaboration with LabCentral, in Lowell, Massachusetts through a collaboration with UMass, in Houston through a collaboration with the Texas Medical Center (TMC), in Toronto through a collaboration with the Ontario Government and the University of Toronto. New JLABS in NYC and Shanghai have been announced, and in February 2018, the Belgium-based JLINX incubator began transitioning into a JLABS, making this the first JLABS in Europe.  For more information about JLABS, please visit jlabs.jnjinnovation.com.

About Johnson & Johnson (China) Investment Ltd

Picture1_0.png

 

 

 

 

强生公司

强生是全球业务分布广泛、综合性的跨国医疗保健企业,业务涉及消费品、制药、医疗器材三大领域,1985年在华创立了第一家合资企业。强生遵循企业信条的价值观,致力于践行“关爱全世界,关注每个人”的健康愿景,以领先的科技研发创造创新的理念、产品和服务,为改善人类健康和福祉而不懈努力。每天,强生遍布世界各地的员工,与他们的合作方一起,为全球消费者和病患带来更健康、更快乐、更长寿的生活。

 

 


 

Seoul Innovation QuickFire Challenge: Robotics & Digital Surgery

JLABS | Lung Cancer QuickFire Challenge
Seoul Innovation QuickFire Challenge: Robotics & Digital Surgery QFC
Challenge ended

KRW 150M (~$134k) + Entrance to Seoul Bio Hub + Mentorship

Digital Health
Surgery

Winners

 

medipixel%20logo_1-1.png

Seoul-based Medipixel is a start-up that applies artificial intelligence (AI) into robotic surgery, starting with percutaneous coronary intervention (PCI). Their AI-based robotic PCI solution helps surgeons choose the most suitable devices and guides devices precisely without human intervention

 

Bilab%20Logo.png

Seoul-based BiLab is a start-up that develops and produces non-invasive continuous monitoring medical devices of cardiopulmonary functions using electrical impedance tomography (EIT) for hypoventilation, hemodynamics, and sleep apnea diagnostics, among other functions.  

The Challenge

seoul_qfc

“5 billion people in the world don’t have access to safe surgery,” as reported by The Lancet in their Global Surgery Report 2030.

 

While patient outcomes in surgery have improved over the past decade - driven by better materials, implant designs, and surgical techniques - major obstacles remain to be addressed. Surgical patients still experience major discrepancies in success, including a 20-40% rate of failed back surgery syndrome (FBSS) according to the NCBI.  And with a rapidly aging world population - expected to grow from just over 900 million to nearly 1.5 billion between 2015 and 2030 according to Forbes– the stakes are higher than ever before. 

Inconsistencies in surgical training and high rates of burnout among orthopedic surgeons are some of the factors contributing to variations in patients outcomes.  At the same time, the high financial burden of associated with pre-, intra-, and post-surgery are being compounded by rising patient demand. The current model is unsustainable as analyzed in the Projection of Surgical Loads of Hip and Knee report[1].

Fortunately, tremendous opportunity awaits. Advancing technology can lead the industry to drastic improvements, a digital ecosystem where technologies enhance surgical performance, help educate surgeons, and guide patients through to full recovery. This digital ecosystem will amplify the surgeon’s ability through personalization, automation, and improved procedural efficiency throughout the continuum of care so that we reduce variability and help improve outcomes. 

The potential of digitally enabled technologies is significant, but we believe that existing solutions are not optimal especially in the area of robotics. Current robotics are large and complicated; they slow procedures down without improving accuracy; they require dedicated support, intensive training and cannot easily be shared between operating rooms or surgeons. 

That’s why Johnson & Johnson Medical Korea Ltd. in collaboration with Seoul Metropolitan Government (SMG) and Korea Health Industry Development Institute (KHIDI) are launching the Seoul Innovation QuickFire Challenge: Robotics & Digital Surgery. Up to two winning robotics and surgical solutions will receive up to KRW 150,000,000 (~$134,000)*, entrance to the Seoul Bio Hub, one year of mentorship and coaching, and access to the JLABS global entrepreneurial community.

 

[1]Gaiser S, Kapoun M. Projection of Surgical Loads of Hip and Knee. Heraeus Medical GmbH, Wehrheim, Germany; Hochschule Niederrhein, Krefeld, Germany

Areas of Interest

We encourage applications from innovators working on all aspects of robotics and digital health related to surgery.  Here’s what we mean: 

  • Patient Engaging Apps
  • Sensors/Wearables
  • Pre-surgery prep/prehab
  • Surgical Decision Support
  • Visualization
  • Robotics
  • Self-Enabled Rehab
  • Health Care or Patient Data Analytics

Why this challenge matters to us

We believe a good idea can come from anywhere, and it’s our goal to find new and innovative technologies that provide solutions to patients from across the world. Working together, we can spark the next great idea that will change the trajectory of health.

Timeline

August 13th, 2018
Applications Open
October 5th, 2018
UTC
Application Deadline
November 14th, 2018
Winner Announcement at Seoul BioMedical International Conference

Apply Now

Submit your idea today!


Don’t miss the deadline

Awards

KRW 150,000,000 (~$134,000)*
  • Entrance to the Seoul Bio Hub
  • Mentorship/Coaching for 1 Year
  • Access to the JLABS global entrepreneurial community
  • *From the KRW 150 million grant, each winner will receive a KRW 70 million cash award and a KRW 5 million free space voucher which must be used toward the rent and utilities at the Seoul Bio Hub for a year

FAQs

Q: What if I’m having trouble accessing the portal/website?

A: Make sure your browser is up to date and accepting cookies. You can contact customer service at [email protected] / if you are having technical difficulties as well.

 

Q: For prizes involving residency at Seoul Bio Hub, what does that entail?

A: For this challenge involving residency at Seoul Bio Hub, that entails the entitlement to rent an office suite at Seoul Bio Hub, of which the size of suites starts from 24m2.  From the KRW 150 million grant, each winner will receive a KRW 70 million cash award and a KRW 5 million free space voucher which must be used toward the rent and utilities at the Seoul Bio Hub for a year.

 

Q: For prizes involving residency, are there any expenses not covered by Seoul Bio Hub?

A: Each winner will be responsible for its monthly rent and utilities. Each winner will receive a voucher to be used to cover one year of rent and utilities at Seoul Bio Hub. Please contact Seoul Bio Hub ([email protected]) for more information on rental cost. 

 

Q: Will JLABS or Seoul Bio Hub pay for my living costs, relocation or visas?

A: No, any additional fees and paperwork are up to the winner.

 

Q: Can I submit supporting documents (for example a video) as part of my application? 

A: You will have the opportunity and are encouraged to upload supporting materials such as slide decks, research papers, and videos as part of your application. You may submit a video along with your typed responses. Maximum length is 2 minutes.

 

Q: Is it ok if some of the information I submit is confidential?

A: Do not submit confidential information. Only non-confidential information should be submitted and anything you submit will be treated as non-confidential.

 

Q: What happens with IP (Intellectual Property)?

A: As this is a no strings attached arrangement, JLABS does not acquire any IP.  Any IP creation and/or protection remains the sole responsibility of the inventors.

 

Q: Is a patent required to apply?

A: No, a patent is not required to apply.  However, you should not submit any information that you wish to keep confidential or that may negatively impact upon the future patentability of your invention.

 

Q: What kind of science / technology is appropriate for the Challenges? 

A: We encourage all to apply. Find out more about what areas we desire to explore here: https://www.jnjinnovation.com/partnering

 

Q: Who is eligible to apply?

A: Each Challenge has its own terms & conditions that can be found prior to filling out the application.

 

Q: What are the specific criteria for application?

A:  Solutions will be evaluated by a panel of reviewers and judges on their ability to meet the following criteria:

  • Potential impact
  • Uniqueness of solution & level of competition in current market
  • Quality & feasibility of technology
  • Team credibility & capabilities
  • Plans for utilizing Seoul Bio Hub
  • Idea submission outlines interest in the innovation ecosystem in Seoul

 

Q: Who can I contact if I have questions about the Challenges or the application process?

A: Please contact [email protected] with any questions.

 

Q: Where do I apply? And do I have to complete the application in one sitting?

A: You can setup an account at http:// jnjawards.fluidreview.com. You are able to save your work and log back in to finish at a later time if needed.

About Johnson & Johnson Innovation

 

jjic_innovation_logo_rgb_virtical_300dpi.png

Johnson & Johnson Innovation LLC focuses on accelerating all stages of innovation worldwide and forming collaborations between entrepreneurs and Johnson & Johnson’s global healthcare businesses. Johnson & Johnson Innovation provides scientists, entrepreneurs and emerging companies with one-stop access to science and technology experts who can facilitate collaborations across the pharmaceutical, medical device and consumer companies of Johnson & Johnson. Under the Johnson & Johnson Innovation umbrella of businesses, we connect with innovators through our regional Innovation Centers, Johnson & Johnson Innovation | JLABS, Johnson & Johnson Innovation – JLINX, Johnson & Johnson Innovation – JJDC, Inc. and our Business Development teams to create customized deals and novel collaborations that speed development of innovations to solve unmet needs in patients. For more information, visit www.jnjinnovation.com or follow

@JNJInnovation.

 

About Johnson & Johnson Innovation, JLABS

 

johnson-johnson-jlabs-7x4.jpgJohnson & Johnson Innovation LLC focuses on accelerating all stages of innovation worldwide and forming collaborations between entrepreneurs and Johnson & Johnson’s global healthcare businesses. Johnson & Johnson Innovation provides scientists, entrepreneurs and emerging companies with one stop access to science and technology experts who can facilitate collaborations across the pharmaceutical, medical device and consumer companies of Johnson & Johnson. Under the Johnson & Johnson Innovation umbrella of businesses, we connect with innovators through our regional Innovation Centers, Johnson & Johnson Innovation, JLABS (JLABS), Johnson & Johnson Innovation – JJDC, Inc. and our Business Development teams to create customized deals and novel collaborations that speed development of innovations to solve unmet needs in patients. For more information, visit www.jnjinnovation.com or follow @JNJInnovation.

Johnson & Johnson Innovation, JLABS (JLABS) is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS achieves this by providing the optimal environment for emerging companies to catalyze growth and optimize their research and development by opening them to vital industry connections, delivering entrepreneurial programs and providing a capital-efficient, flexible platform where they can transform the scientific discoveries of today into the breakthrough healthcare solutions of tomorrow.  At JLABS we value great ideas and are passionate about removing obstacles to success to help innovators unleash the potential of their early scientific discoveries.  JLABS is a no-strings-attached model, which means entrepreneurs are free to develop their science while holding on to their intellectual property.  JLABS is open to entrepreneurs across a broad healthcare spectrum including pharmaceutical, medical device, consumer and digital health sectors.

JLABS currently has locations in innovation hot spots across the world and produces entrepreneurial programs and campaigns to seek out the best science, like the QuickFire Challenges around the globe. The JLABS flagship opened in 2012 in San Diego at Janssen's West Coast Research Center, and since then, has established two locations in San Francisco - one through a collaboration with the California Institute for Quantitative Biosciences (QB3) and a second standalone facility in South San Francisco.  JLABS is also located in Boston through a collaboration with LabCentral, in Lowell, Massachusetts through a collaboration with UMass, in Houston through a collaboration with the Texas Medical Center (TMC), in Toronto through a collaboration with the Ontario Government and the University of Toronto. New JLABS in NYC and Shanghai have been announced, and in February 2018, the Belgium-based JLINX incubator began transitioning into a JLABS, making this the first JLABS in Europe.  For more information about JLABS, please visit www.jlabs.jnjinnovation.com.

 

About the Seoul Metropolitan Government

 

Picture3.png

 

 

Seoul is a global city located at the center of Northeast Asia characterized by easy access to metropolitan cities around the world and convenient living conditions, particularly with nine (9) subway lines, 6,000 bus stops, and 22 international schools. 

The Seoul Metropolitan Area is an optimal location to foster technology-oriented venture firms as it houses more than 20,000 research institutes, 139 universities, and 133 general hospitals, concentrating top-caliber workforce and technology in a single location.

The Hongneung Biomedical Cluster, home to Seoul Bio Hub, which is slated to open in September 2017, houses national research institutes (KIST,etc.), research-oriented hospitals, and universities. The Seoul Metropolitan Government plans to offer facilities and equipment for the fast growth of technologically advanced startups and help businesses, researchers, and businessmen develop and commercialize innovative technologies via support in investment, administration, and information services.

 

About Seoul Bio Hub

 

Picture2.pngSeoul Bio Hub, located in northern Seoul and began operations in October 2017, is a life science innovation center sponsored by SMG and operated by KHIDI. The key function is to support early stage life science companies’ growth and commercialization by providing full-service wet laboratory and office spaces, shared equipment, networking events, training programs, and investor relation opportunities. As the only biotech startup platform located in Seoul, it leverages its geographical advantages to accelerate the startup ecosystem, by facilitating cooperative networks among research-driven hospitals, universities, national research institutes, and venture capitals within close vicinity. For more information, please visit http://www.seoulbiohub.kr.

 

About Korea Health Industry Development Institute (KHIDI)

 

KHIDI is a government-affiliated institution which performs professional and systematic support to develop domestic healthcare industry and enhance healthcare services. Since its establishment in 1999, KHIDI has led expansion of healthcare research and development investment and building competitiveness of Korea's healthcare industry, i.e., health services, pharmaceuticals, medical devices, food and beauty-cosmetic. KHIDI is designated as an operating body of Seoul Bio Hub, and plans to utilize its infrastructure and network to facilitate cooperation with relevant stakeholders. For more information, please visit http://www.khidi.or.kr/eps.

 

About the Johnson & Johnson Medical Devices Companies

 

The Johnson & Johnson Medical Devices Companies’ purpose is to reach more patients and restore more lives. Having advanced patient care for more than a century, these companies represent an unparalleled breadth of products, services, programs and research and development capabilities in surgical technology, orthopaedics, cardiovascular and specialty solutions with an offering directed at delivering clinical and economic value to health care systems worldwide.

            

JLABS @ M2D2 QuickFire Challenge

JLABS @ M2D2 QuickFire Challenge
Challenge ended

Residency at JLABS @ M2D2

Diabetes
Neurovascular
Orthopedics
Surgery
Vision care
Image paragraph

Third Pole is producing next generation cardio-pulmonary therapies that expand patient access. Our first product creates inhaled nitric oxide on-demand, on-site from air. Powered by this innovative portable technology licensed from Massachusetts General Hospital we eliminate the need for cumbersome compressed gas cylinders and enable the worldwide use of inhaled NO in settings outside of acute care.

The Challenge

We are looking for game-changing early-stage medical device innovations and therapeutic platforms across Johnson & Johnson’s strategic areas of interest:

  • Cardiovascular
  • Diabetes
  • Neurovascular
  • Orthopedics
  • Surgery
  • Vision Care

Entrants must be committed to conducting their project at the M2D2 space in Lowell, MA.

Rewards and benefits

Space at JLABS @ M2D2

Why this challenge matters to us

At Johnson & Johnson Innovation, we believe the next great idea can come from anywhere – and that it’s just as likely to come from outside of our walls as from inside our research labs. That’s why Johnson & Johnson Innovation is excited to announce JLABS @ M2D2, our accelerator initiative in partnership with the northeast region’s premier medtech incubator, University of Massachusetts Medical Device Development Center (M2D2) in Lowell, Massachusetts. JLABS @ M2D2 is our seventh JLABS facility and the first specifically focused on the early-stage medical device ecosystem.

Timeline

PST
Deadline to apply
PST
Announcement of winners

Check out the blog post on the J&J website!

JLABS @ Toronto QuickFire Challenge

JLABS @ Toronto QuickFire Challenge
Challenge ended

Residency at JLABS

Consumer Health
Digital Health
Therapeutics

Winners

Image paragraph

A4i is a digital health innovation company that provides clinically-proven mobile interventions to significantly enhance treatment engagement and quality of life for individuals with psychosis and other major mental health challenges.

Image paragraph

An innovative gene therapy company focused on immune-oncology and rare diseases.

Image paragraph

Developing novel therapeutics for metastatic cancers employing a comprehensive approach to reverse the metastatic state of tumor cells.

Image paragraph

Achieving high-precision personalized cancer therapy with multimodal nano imaging agents: lead application in image-guided surgery”.

Image paragraph

Creators of a seizure tracking tool that uses devices patients already own and wear. 

Image paragraph

Regular molds have one shape; PinPress is a shape-shifting tool that gives you a thousand molds in one.

Image paragraph

Helping people enjoy the sun with a smart indicator of ultraviolet light that changes colour to warn people of their sun exposure.

The Challenge

In honor of the upcoming Grand Opening of JLABS @ Toronto, Johnson & Johnson Innovation has launched a QuickFire Challenge to award new game-changing early-stage innovation companies with the use of a bench, workstation and access to the JLABS @ Toronto community for one year. In addition, all winners will receive memberships from BIOTECANADA and OBIO , and the Medical Device winner will receive a membership from Medec.

JLABS @ LabCentral QuickFire Challenge

JLABS @ LabCentral QuickFire Challenge
Challenge ended

Residency at JLABS

Consumer Health
Digital Health

Winners

Image paragraph

Cyteir Therapeutics is developing new drugs to treat cancer and chronic autoimmunity.

Image paragraph

Riparian Pharmaceuticals is an early-stage biotechnology company employing innovative models of vascular pathophysiology to discover novel therapeutics.

Image paragraph

XTuit Pharmaceuticals is pursuing novel approaches to improving cancer therapy by targeting the tumor microenvironment.

The Challenge

In honor of the upcoming Grand Opening of JLABS @ LabCentral, Johnson & Johnson Innovation has launched a QuickFire Challenge to award new game-changing early-stage innovation companies with the use of a bench, workstation and access to the JLABS @ LabCentral community for one year.

Advancing the Safe Use of Healthcare Products QuickFire Challenge

Advancing the Safe Use of Healthcare Products QuickFire Challenge
Advancing the Safe Use of Healthcare Products QuickFire Challenge
Challenge ended

Up to $200,000 USD*

Consumer Health
Digital Health
Surgery

Winner

Image paragraph

CertaDoseTM offers a unique measuring system that helps eliminate dosing errors in kids by using any of the industry standard methods of estimating a patient’s weight, including length and age, and automatically converts that weight to the appropriate dosage on our color-coded syringe.  CertaDoseTM is an FDA-cleared syringe clinically proven to reduce critical dosing errors to zero. Each syringe is labeled with easy to recognize color zones that match the Broselow® color system to help clinicians verify the correct dose during critical, time-sensitive situations.

The Challenge

Image paragraph

At the Johnson & Johnson Office of the Chief Medical Officer (OCMO) we strive to enable healthcare practitioners, physicians, surgeons, patients and consumers to use our products safely by providing the most complete information and the best education and training we can.

To that end, Johnson & Johnson Innovation and the OCMO are looking to reward up to $200,000 in multiple grants, and one year of JLABS space, to the individuals or teams who submit the best ideas on how to educate, inform and provide clarity around healthcare product safety.

Rewards and benefits

Up to $200,000 USD*
  • *in grants for multiple winners
  • Entrance to an available JLABS
  • Mentoring & Coaching

QuickFire Challenge innovation focus areas

Empowering patients and consumers to make more informed healthcare decisions by providing better information and education about the safety of healthcare products (pharmaceuticals, medical devices and consumer products).

This challenge focus area seeks ways to maximize consumer and patient education and understanding of healthcare products and their safety and efficacy, including medical devices, pharmaceuticals and consumer products.

The objective is to empower patients, consumers and healthcare providers to make more informed decisions and obtain maximum benefit from product use through greater understanding of safety data and by ensuring more effective communication and enhancing education.

Image paragraph

Improving training and development for surgeons by identifying new models that simulate the operating room environment.

This focus area seeks new and robust models and methods to evaluate medical devices used by surgeons in a simulated environment representative of operating room procedures, with the goal of helping the surgeon understand how to safely and effectively use a medical device and understand variability in device and performance/outcome.

Entries should focus on soft tissue models that anatomically represent organ-specific anatomic features and biological properties, such as tissue injury, bleeding and clotting responses.

Image paragraph

Empowering patients and consumers to more safely administer and handle healthcare products.

The third focus area seeks ways to address the challenge of prescription medication errors. Entries should identify patient- and consumer-focused devices, solutions or platforms that will prevent errors and solutions to promote safe storage and administration or extend the shelf life of prescription, over-the-counter or cosmetic products.

Image paragraph

Timeline

CST
Applications Open
CST
Submission Deadline
CST
Winner Announced

Why this challenge matters to us

True benefit from healthcare products requires an unrelenting focus on patient- and consumer-centered safety, a principle that is at the heart of Johnson & Johnson’s Credo and is embodied in the mission of the Office of the Chief Medical Officer (OCMO).  Working to ensure that J&J is developing and making available the safest products possible is what the nearly 1000 employees of OCMO work towards each day.  Always looking for better ways to address safety on behalf of patients and consumers, we are embarking on a Quickfire Challenge to identify new and innovative ideas to increase the safe use of our products.

Application process

Solutions will be evaluated by a panel of reviewers and judges on their ability to meet the following criteria:

  • Potential to impact healthcare outcomes / move the needle on medical safety
  • Uniqueness of solution & level of competition in current market
  • Quality & feasibility of technology
  • Team credibility & capabilities
  • Clarity of plan: Milestones & defined go/no go decisions

Deadline to apply is May 24, 2017
Winner(s) will be announced in November

About Johnson & Johnson Office of the Chief Medical Officer

Established in 2013, the Johnson & Johnson Office of the Chief Medical Officer (OCMO) is accountable for bringing scientific excellence, bioethics- and values-driven decision-making, as well as a commitment to transparency and medical safety assessments that are independent of commercial interests, to the many efforts that keep patients and consumers at the heart of everything we do. The OCMO has oversight across Johnson & Johnson for medical safety, epidemiology, R&D operations and creating and maintaining global bioethical policies.

 

About Johnson & Johnson Innovation

Johnson & Johnson Innovation LLC focuses on accelerating all stages of innovation worldwide and forming collaborations between entrepreneurs and Johnson & Johnson’s global healthcare businesses. Johnson & Johnson Innovation provides scientists, entrepreneurs and emerging companies with one-stop access to science and technology experts who can facilitate collaborations across the pharmaceutical, medical device and consumer companies of Johnson & Johnson. Under the Johnson & Johnson Innovation umbrella of businesses, we connect with innovators through our regional Innovation Centers, Johnson & Johnson Innovation | JLABS, Johnson & Johnson Innovation – JLINX, Johnson & Johnson Innovation – JJDC, Inc. and our Business Development teams to create customized deals and novel collaborations that speed development of innovations to solve unmet needs in patients. For more information, visit www.jnjinnovation.com or follow @JNJInnovation.

 

About Johnson & Johnson Innovation, JLABS

Johnson & Johnson Innovation, JLABS (JLABS) is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS achieves this by providing the optimal environment for emerging companies to catalyze growth and optimize their research and development by opening them to vital industry connections, delivering entrepreneurial programs and providing a capital-efficient, flexible platform where they can transform the scientific discoveries of today into the breakthrough healthcare solutions of tomorrow.  At JLABS we value great ideas and are passionate about removing obstacles to success to help innovators unleash the potential of their early scientific discoveries.  JLABS is a no-strings-attached model, which means entrepreneurs are free to develop their science while holding on to their intellectual property.  JLABS is open to entrepreneurs across a broad healthcare spectrum including pharmaceutical, medical device, consumer and digital health sectors.

JLABS currently has nine locations in innovation hot spots across North America and produces entrepreneurial programs and campaigns to seek out the best science, like the QuickFire Challenges around the globe. The JLABS flagship opened in 2012 in San Diego at Janssen's West Coast Research Center, and since then, has established two locations in San Francisco - one through a collaboration with the California Institute for Quantitative Biosciences (QB3) and a second standalone facility in South San Francisco.  JLABS is also located in Boston through a collaboration with LabCentral, in Lowell, Massachusetts through a collaboration with UMass, in Houston through a collaboration with the Texas Medical Center (TMC), in Toronto through a collaboration with the Ontario Government and the University of Toronto and a new JLABS @ NYC (in collaboration with the New York Genome Center -opening in 2018).  For more information about JLABS, please visit www.jlabs.jnjinnovation.com.

Image paragraph
Image paragraph

You can find our press release here.

Seoul Innovation QuickFire Challenge

Seoul Innovation QuickFire Challenge
Challenge ended

KRW 150,000,000*

Digital Health
Therapeutics

Winners

Image paragraph

GPOWER Inc. is an IoT skincare company providing hardware and software solutions to help monitor, manage and improve skin health.

Company website : www.mybarrierskin.com

Image paragraph

Nu Eyne is a medical device company that focuses on treating ophthalmological disorders, such as dry eye syndrome and eye pain, by applying neuromodulation and tissue engineering.

Company website: www.nueyne.com

The Challenge

Image paragraph

Johnson & Johnson Innovation, JLABS (JLABS) in collaboration with Seoul Metropolitan Government (SMG), Korea Health Industry Development Institute (KHIDI),  Janssen Korea Ltd. and Johnson & Johnson Medical Korea Ltd. have launched the Seoul Innovation QuickFire Challenge to attract global game-changing, early stage innovations. Two winners with the best idea, technology, or solution that will address a health need for the world's population will be a receipt of up to KRW 150,000,000 (approximately US$134,000) in grant funding, entrance to the Seoul Bio Hub (each winner will receive KRW 70,000,000 cash award and a space voucher for KRW 5,000,000 which may be used toward the rent and utilities at the Seoul Bio Hub), and a year of mentorship and coaching.

Rewards and benefits

KRW 150,000,000*
  • *in funding for up to two winners
  • Entrance to the Seoul Bio Hub
  • (*each winner will receive KRW 70,000,000 cash award and a space voucher for KRW 5,000,000 which may be used toward the rent and utilities at the Seoul Bio Hub)
  • A year of mentorship and coaching from Johnson & Johnson Innovation and KHIDI

Areas of interest

This global competition will award the person or team(s) who submits the best idea, technology, or solution focused in the following areas:

  • Health technologies
  • Medical devices
  • Therapeutics

In the following sectors:

  • Bone & join disease
  • Cardiovascular and metabolic disease
  • Immunology
  • Infectious disease
  • Neuroscience
  • Oncology

Why this challenge matters to us

At Johnson & Johnson Innovation, we believe a good idea can come from anywhere, and it’s our goal to find new and innovative technologies that provide solutions to patients from across the world. Working together, we can spark the next great idea that will change the trajectory of health. Seoul, Korea has a robust healthcare innovation ecosystem and Johnson & Johnson is excited to be a part of it through this QuickFire Challenge.

Frequently Asked Questions

What is being awarded and to how many innovators/companies?

Up to two winners will be awarded a combined KRW 150,000,000 & entrance to the Seoul Bio Hub. Each winner will receive KRW 70,000,000 cash award and a space voucher for KRW 5,000,000 which may be used toward the rent and utilities at the Seoul Bio Hub.

Where do I apply?

You can apply through https://jnjawards.fluidreview.com/

Who is eligible to apply?

We encourage applications from everyone interested in the Seoul Innovation QuickFire Challenge from across the globe; however, per the terms and conditions, not all applicants may be eligible to win the Seoul Innovation QuickFire Challenge.

Applicants may be individuals, entrepreneurs, academics, biotech researchers or an early-stage company that is less than 60 months old.

Applicant must not be in default of payment of dues owed to any financial institutions and/or default in payment of any national and/or local taxes in South Korea.

While all potential applicants are encouraged to apply, those that are Health Care Providers (“HCPs”), Government Officials (“GOs”) (see definitions below), which for purposes here include any individual who is a “public official” as defined under the Act on Prohibition of Improper Requests and Provision/Receipt of Money or Valuables, or any organization affiliated with either, will be subjected to additional review, and may not be ultimately eligible to continue with the application and selection process.

Definitions:

Government Official or “GO” means any official or employee of a government agency or instrumentality of the government including but is not limited to a political party, party official or candidate, or public international organizations. It also includes individuals representing himself or herself as a GO, for example, a customs official, inspector, auditor, investigator, elected official, or employee of a government ministry or agency.  Note that this definition includes agents or employees of some non-governmental (NGO) organizations where those organizations perform quasi-governmental services such as distribution of drugs and medical devices or delivery of health care services, an individual who is an agent or consultant to a government agency, or provides a primary business address at a government facility, uses a military title  or rank, supplies an email address associated with a government entity or is otherwise known or believed to be a government employee. Health Ministries and government-owned hospitals often employ HCPs who may be GOs under local law. A private HCP that provides consulting services or otherwise acts as an agent of the government, these individuals should be considered Government Officials. It includes any individual who is a “public official” as defined under the Act on Prohibition of Improper Requests and Provision/Receipt of Money and Valuables of Korea.

“Health Care Provider” or “HCP” means:

  • All physicians; and 
  • Any other individual, institution or entity with the ability to prescribe, acquire or influence the prescription or acquisition of the Johnson & Johnson (including its affiliates and subsidiaries) products or services at issue, and either of the following: 
  • The products at issue are regulated or registered as medicinal products or devices (or their equivalents) in the applicable country; or
  • The products or services at issue are subject to reimbursement by government or third parties; or, are offered for sale with products or services subject to such reimbursement.

Examples of HCPs -- depending on the nature of the products or services at issue -- may include, but are not limited to, doctors, nurses, physician assistants, pharmacists, other para-medical staff, members of product formulary committees, health economists, key opinion leaders including scientists and/or PhD’s, clinical investigators and researchers, administrative and management employees of private and public hospitals, HCPs-in-training and medical societies.

What sectors are you looking for?

Healthcare solutions from across the globe in the following areas::

  • Health technologies
  • Medical devices
  • Therapeutics

In the following sectors:

  • Bone & join disease
  • Cardiovascular and metabolic disease
  • Immunology
  • Infectious disease
  • Neuroscience
  • Oncology
What are the specific criteria for application?

All applicants must outline their interest in Seoul, South Korea, including plans to work in Seoul and engage with the local ecosystem as well as how the mentorship can critically support their innovation. Applicants may be individuals, entrepreneurs, academics, biotech researchers or an early-stage company that is less than 60 months old and must not be in default of payment of dues owed to any financial institutions and/or default in payment of any national and/or local taxes in South Korea.

Do applicants have to reside in Korea in order to apply?

No, this is a global challenge. However, if selected as a winner or finalist, at least one core team member of the applicant company must reside in the Seoul Bio Hub for no less than 1 year (each winner will receive a space voucher for KRW 5,000,000 which may be used toward the rent and utilities at the Seoul Bio Hub).

Can I submit supporting documents (for example a video) as part of my application?

You will have the opportunity and are encouraged to upload supporting materials such as slide decks, research papers, and videos as part of your application. You may submit a video along with your typed responses. Maximum length is 2 minutes.

Is it ok if some of the information I submit is confidential?

Do not submit confidential information. Only non-confidential information should be submitted.

*For further information on eligibility for this QuickFire Challenge, please refer to the Terms & Conditions presented in your application form.

Application process

Solutions will be evaluated by a panel of reviewers and judges on their ability to meet the following criteria:

  • Potential impact
  • Uniqueness of solution & level of competition in current market
  • Quality & feasibility of technology
  • Team credibility & capabilities
  • Clarity of plan: Milestones for the next 12 months
  • Idea submission outlines interest in the innovation ecosystem in Seoul, South Korea

Deadline to apply is September 29, 2017
Winner(s) will be announced in December.

Timeline

KST
Applications Open
KST
Submission Deadline
KST
Judging Process Begins
KST
Winners Announced at Seoul Bio Hub

About Johnson & Johnson Innovation

Johnson & Johnson Innovation focuses on accelerating all stages of innovation worldwide and forming collaborations between entrepreneurs and Johnson & Johnson’s global healthcare businesses. Johnson & Johnson Innovation provides scientists, entrepreneurs and emerging companies with one-stop access to science and technology experts who can facilitate collaborations across the pharmaceutical, medical device and consumer companies of Johnson & Johnson. Under the Johnson & Johnson Innovation umbrella of businesses, we connect with innovators through our regional Innovation Centers, Johnson & Johnson Innovation | JLABS, Johnson & Johnson Innovation - JLINX, Johnson & Johnson Innovation – JJDC and our Business Development teams to create customized deals and novel 4 collaborations that speed development of innovations to solve unmet needs in patients. For more information, visit www.jnjinnovation.com or follow @JNJInnovation.

 

About Johnson & Johnson Innovation, JLABS

Johnson & Johnson Innovation, JLABS (JLABS) is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS achieves this by providing the optimal environment for emerging companies to catalyze growth and optimize their research and development by opening them to vital industry connections, delivering entrepreneurial programs and providing a capital-efficient, flexible platform where they can transform the scientific discoveries of today into the breakthrough healthcare solutions of tomorrow.  At JLABS we value great ideas and are passionate about removing obstacles to success to help innovators unleash the potential of their early scientific discoveries.  JLABS is a no-strings-attached model, which means entrepreneurs are free to develop their science while holding on to their intellectual property.  JLABS is open to entrepreneurs across a broad healthcare spectrum including pharmaceutical, medical device, consumer and digital health sectors.


JLABS currently has nine locations in innovation hot spots across North America and produces entrepreneurial programs and campaigns to seek out the best science, like the QuickFire Challenges around the globe. The JLABS flagship opened in 2012 in San Diego at Janssen's West Coast Research Center, and since then, has established two locations in San Francisco - one through a collaboration with the California Institute for Quantitative Biosciences (QB3) and a second standalone facility in South San Francisco.  JLABS is also located in Boston through a collaboration with LabCentral, in Lowell, Massachusetts through a collaboration with UMass, in Houston through a collaboration with the Texas Medical Center (TMC), in Toronto through a collaboration with the Ontario Government and the University of Toronto and a new JLABS @ NYC (in collaboration with the New York Genome Center -opening in 2018).  For more information about JLABS, please visit www.jlabs.jnjinnovation.com.

 

About Janssen Pharmaceutical Companies

At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science. We are Janssen. We collaborate with the world for the health of everyone in it. Learn more at www.janssen.com/korea .


About the Johnson & Johnson Medical Devices Companies

The Johnson & Johnson Medical Devices Companies’ purpose is to reach more patients and restore more lives. Having advanced patient care for more than a century, these companies represent an unparalleled breadth of products, services, programs and research and development capabilities in surgical technology, orthopaedics, cardiovascular and specialty solutions with an offering directed at delivering clinical and economic value to health care systems worldwide.

 

About Seoul Metropolitan Government (SMG)

Seoul is a global city located at the center of Northeast Asia characterized by easy access to metropolitan cities around the world and convenient living conditions, particularly with nine (9) subway lines, 6,000 bus stops, and 22 international schools.

The Seoul Metropolitan Area is an optimal location to foster technology-oriented venture firms as it houses more than 20,000 research institutes, 139 universities, and 133 general hospitals, concentrating top-caliber workforce and technology in a single location.

The Hongneung Biomedical Cluster, home to Seoul Bio Hub, which is slated to open in september 2017, houses national research institutes (KIST,etc.), research-oriented hospitals, and universities. The Seoul Metropolitan Government plans to offer facilities and equipment for the fast growth of technologically advanced startups and help businesses, researchers, and businessmen develop and commercialize innovative technologies via support in investment, administration, and information services.

 

About Korea Health Industry Development Institute (KHIDI)

KHIDI is a government-affiliated institution which performs professional and systematic support to develop domestic healthcare industry and enhance healthcare services. Since its establishment in 1999, KHIDI has led expansion of healthcare research and development investment and building competitiveness of Korea's healthcare industry, i.e., health services, pharmaceuticals, medical devices, food and beauty-cosmetic. KHIDI is designated as an operating body of Seoul Bio Hub, and plans to utilize its infrastructure and network to facilitate cooperation with relevant stakeholders. For more information, please visit http://www.khidi.or.kr/eps.

 

About Seoul Bio Hub

Seoul Bio Hub, located in northern Seoul and slated to begin operations in September 2017, is a life science innovation center sponsored by SMG and operated by KHIDI. The key function is to support early stage life science companies’ growth and commercialization by providing full-service wet laboratory and office spaces, shared equipment, networking events, training programs, and investor relation opportunities. As the only biotech startup platform located in Seoul, it leverages its geographical advantages to accelerate the startup ecosystem, by facilitating cooperative networks among research-driven hospitals, universities, national research institutes, and venture capitals within close vicinity. For more information, please visit http://www.seoulbiohub.kr.

bottom-banner-version-5.png

 

You can find our press release here.

CDI @ TMC QuickFire Challenge

CDI @ TMC QuickFire Challenge
Challenge ended

Up to $400,000 USD*

Obesity
Osteoarthritis
Surgical Oncology

Winners

smc_qfc_mtc_allwinnersv2.jpg

Image paragraph

LifeSprout is developing the next-generation of synthetic soft tissue substitutes for aesthetic and oncologic restoration.

Image paragraph

Intelligent Implants enhance, directs and monitors bone growth in real-rime using wireless implantable electronics.

Barostitch is a first-of-its-kind medical device for the minimally invasive, no-touch closure of calcified, large-bore femoral artery access sites following structural heart interventions.

The Challenge

Image paragraph

In conjunction with the Grand Opening of the Center for Device Innovation (CDI @ TMC) in the Fall 2017, Johnson & Johnson Innovation and Johnson & Johnson Medical Devices have launched the CDI @ TMC QuickFire Challenge, a device-focused challenge aimed at game-changing early-stage medical device innovations across strategic areas of interest for Johnson & Johnson Medical Devices, with an emphasis on Surgical Oncology and/or Obesity.


Johnson & Johnson Innovation will award a grant up to $50,000 to the top solutions, one year of paid lab space at JLABS @ TMC in Houston, Texas, including access to the device prototyping lab, and  mentorship and coaching from Johnson & Johnson Medical Devices experts including the world renowned Billy Cohn. Additionally, Johnson & Johnson Innovation has partnered with angelMD, an investment platform and marketplace connecting innovative medical startups, physicians, investors, and industry partners to provide the winning solution an additional $100,000 investment from its catalyst fund, plus angelMD will feature the top finalists on its web platform for syndicate partners to invest up to an additional $250,000.


Applications open Tuesday, April 25 and the deadline to apply is Wednesday, June 28, 2017. Winners will be announced at The MedTech Conference in San Jose, CA September 25-27, 2017.

Rewards and benefits

Up to $400,000 USD*
  • *in grants for multiple winners
  • Entrance to an available JLABS
  • Mentoring & Coaching

QuickFire Challenge innovation focus areas

This QuickFire Challenge is looking for companies with a focus on Surgical Oncology and / or Obesity, however, other device companies that align with strategic areas of interest for Johnson & Johnson Medical Devices will be considered. Areas of interest include:

Surgical Oncology - Improved treatment options with reduced complications and better outcomes, Minimally invasive procedures

Image paragraph

Obesity - More durable interventions across the continuum, Prevent or reduce morbidities of obesity

Image paragraph

Osteoporosis - Minimize OP fracture rate, improve healing and address fragile bone

Image paragraph

Osteoarthritis - Early interventions to prevent progression, Better surgical outcomes in advanced disease

Image paragraph

Cardiovascular - Durable, effective interventions to improve outcomes in AFIB and structural heart conditions (e.g. CHF)

Image paragraph

Timeline

EST
Challenge Opens
EST
Submission Deadline
PST
Winners announced at The MedTech Conference in San Jose, September 25-27, 2017

Why this challenge matters to us

The Johnson & Johnson Medical Devices have a successful history in creating new markets, delivering breakthrough innovation and establishing strong partnerships built on a shared vision. We believe a good idea can come from anywhere, and it’s our goal to break through the noise of the crowded device landscape and find new and innovative technologies that provide minimally invasive solutions to patients.

Application Process

Solutions will be evaluated by a panel of reviewers and judges on their ability to meet the following criteria:

  • Potential to impact healthcare outcomes in a strategic area of interest
  • Uniqueness of solution & level of competition in current market
  • Quality & feasibility of technology
  • Team credibility & capabilities
  • Clarity of plan: Milestones & defined go/no go decisions

About Johnson & Johnson Innovation, JLABS

Johnson & Johnson Innovation, JLABS (JLABS) is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS achieves this by providing the optimal environment for emerging companies to catalyze growth and optimize their research and development by opening them to vital industry connections, delivering entrepreneurial programs and providing a capital-efficient, flexible platform where they can transform the scientific discoveries of today into the breakthrough healthcare solutions of tomorrow.  At JLABS we value great ideas and are passionate about removing obstacles to success to help innovators unleash the potential of their early scientific discoveries.  JLABS is a no-strings-attached model, which means entrepreneurs are free to develop their science while holding on to their intellectual property.  JLABS is open to entrepreneurs across a broad healthcare spectrum including pharmaceutical, medical device, consumer and digital health sectors.

JLABS currently has nine locations in innovation hot spots across North America and produces entrepreneurial programs and campaigns to seek out the best science, like the QuickFire Challenges around the globe. The JLABS flagship opened in 2012 in San Diego at Janssen's West Coast Research Center, and since then, has established two locations in San Francisco - one through a collaboration with the California Institute for Quantitative Biosciences (QB3) and a second standalone facility in South San Francisco.  JLABS is also located in Boston through a collaboration with LabCentral, in Lowell, Massachusetts through a collaboration with UMass, in Houston through a collaboration with the Texas Medical Center (TMC), in Toronto through a collaboration with the Ontario Government and the University of Toronto and a new JLABS @ NYC (in collaboration with the New York Genome Center -opening in 2018).  For more information about JLABS, please visit www.jlabs.jnjinnovation.com.


About Johnson & Johnson Medical Devices

Making significant contributions to surgery for over a century, the Johnson & Johnson Medical Devices Companies are in the business of reaching more patients and restoring more lives. We represent the most comprehensive surgical technology and specialty solutions business worldwide, offering an unparalleled breadth of products, services, programs and research and development capabilities directed at advancing patient care while delivering clinical and economic value to health care systems.


About the Center for Device Innovation @ TMC

The Center for Device Innovation @ Texas Medical Center (CDI @ TMC) is a new collaboration (opening mid-2017) that aims to accelerate end-to-end development of breakthrough medical devices. CDI @ TMC will include multiple components to accelerate new medical technologies from concept through commercialization, including a medical device engineering studio housed at the TMC Innovation Institute. This state-of-the-art “maker space” will be home to R&D staff of the Johnson & Johnson Medical Devices Companies and will be used to accelerate both select internal projects and strategically aligned ventures of Johnson & Johnson Medical Devices.


About angelMD

angelMD is an investment platform and marketplace connecting innovative medical startups, physicians, investors, and industry partners. Leading physicians from all over the US have joined the angelMD Scientific Advisory Board and Leaders Club to help source, evaluate and advise companies in biotechnology, medical device and healthcare technology. For more information, visit www.angelmd.co.